MG

Muh Geot Wong

University of Sydney

Sydney NSW, Australia
4.00/5 · 8 reviews

Rate Professor Muh Geot Wong

5 Star3
4 Star2
3 Star3
2 Star0
1 Star0
5.008/20/2025

Encourages students to ask questions.

3.007/2/2025

This comment is not public.

3.007/2/2025

This comment is not public.

3.007/2/2025

This comment is not public.

4.005/21/2025

Always fair, encouraging, and motivating.

5.003/31/2025

Helps students see their full potential.

Page 1 of 2

About Muh

Muh Geot Wong is an Associate Professor of Medicine (Nephrology) in the Faculty of Medicine and Health at the University of Sydney. He earned his MBBS from the Manipal Academy of Higher Education in 1999, PhD from the University of Sydney in 2011, FRACP in 2009, MRCP (UK) in 2002, and was awarded specialist status in Internal Medicine and Nephrology by the Academy of Medicine Malaysia in 2007. His career trajectory includes a research fellowship in Japan in 2006 studying animal models of chronic kidney disease, PhD research under Professor Carol Pollock identifying therapeutic agents against kidney fibrosis, and clinical appointments as Senior Consultant Nephrologist and Director of Renal Research at Concord Repatriation General Hospital since 2022, Senior Staff Specialist at Royal North Shore Hospital, Senior Clinical Lecturer at the University of Sydney and University of New South Wales, VMO Nephrologist at Sydney Adventist Hospital since 2011, and Senior Research Fellow at The George Institute for Global Health and the Kolling Institute.

Wong's academic interests center on the pathomechanisms of kidney fibrosis and developing clinical and pre-clinical strategies to delay chronic kidney disease progression in glomerular diseases, including IgA nephropathy, focal segmental glomerulosclerosis, diabetic nephropathy, and management of associated cardiovascular complications. Key publications include 'The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study - trial design and baseline characteristics' (American Journal of Nephrology, 2021), 'Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND)' (Lancet Diabetes & Endocrinology, 2020), 'Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy' (JAMA, 2022), 'Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis' (Diabetes, Obesity and Metabolism, 2019), and contributions to the Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease (Nephrology, 2020). He influences the field through leadership as Chair of the Education Committee of the Asia Pacific Society of Nephrology, Chair of the Oceania South East Asia Regional Board of the International Society of Nephrology, steering committee member of the Sydney Local Health District Clinical Trial group, and Co-Chair of the local organising committee for the Australia New Zealand Society of Nephrology Annual Scientific Meeting in Sydney 2022.

Professional Email: muhgeot.wong@sydney.edu.au